Is Pyxis Oncology Stock a Good Investment?
Pyxis Oncology Investment Advice | PYXS |
- Examine Pyxis Oncology's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Pyxis Oncology's leadership team and their track record. Good management can help Pyxis Oncology navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Pyxis Oncology's business and its evolving consumer preferences.
- Compare Pyxis Oncology's performance and market position to its competitors. Analyze how Pyxis Oncology is positioned in terms of product offerings, innovation, and market share.
- Check if Pyxis Oncology pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Pyxis Oncology's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Pyxis Oncology stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Pyxis Oncology is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Solid | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Small | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Pyxis Oncology Stock
Researching Pyxis Oncology's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 23.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.59. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pyxis Oncology has Price/Earnings To Growth (PEG) ratio of 0.01. The entity recorded a loss per share of 1.59. The firm had not issued any dividends in recent years.
To determine if Pyxis Oncology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pyxis Oncology's research are outlined below:
| Pyxis Oncology is way too risky over 90 days horizon | |
| Pyxis Oncology appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 16.15 M. Net Loss for the year was (77.33 M) with profit before overhead, payroll, taxes, and interest of 2.82 M. | |
| Pyxis Oncology currently holds about 223.36 M in cash with (57.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Pyxis Oncology has a poor financial position based on the latest SEC disclosures | |
| Roughly 23.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Pyxis Oncology, Inc.s top owners are retail investors with percent stake, while 21 percent is held by institutions |
Pyxis Oncology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pyxis Oncology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pyxis Oncology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Pyxis Oncology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Pyxis Oncology's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-08-14 | 2025-06-30 | -0.34 | -0.3 | 0.04 | 11 | ||
2025-06-11 | 2025-03-31 | -0.24 | -0.35 | -0.11 | 45 | ||
2024-03-21 | 2023-12-31 | -0.47 | -0.33 | 0.14 | 29 | ||
2024-05-14 | 2024-03-31 | -0.24 | -0.06 | 0.18 | 75 | ||
2023-08-11 | 2023-06-30 | -0.65 | -0.41 | 0.24 | 36 | ||
2023-05-11 | 2023-03-31 | -0.9 | -0.55 | 0.35 | 38 | ||
2022-05-13 | 2022-03-31 | -0.61 | -0.97 | -0.36 | 59 | ||
2025-03-19 | 2024-12-31 | -0.32 | -1.32 | -1.0 | 312 |
Pyxis Oncology Target Price Consensus
Pyxis target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Pyxis Oncology's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 7 | Strong Buy |
Most Pyxis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Pyxis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Pyxis Oncology, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationPyxis Oncology Target Price Projection
Pyxis Oncology's current and average target prices are 2.50 and 6.00, respectively. The current price of Pyxis Oncology is the price at which Pyxis Oncology is currently trading. On the other hand, Pyxis Oncology's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Pyxis Oncology Market Quote on 4th of October 2025
Target Price
Analyst Consensus On Pyxis Oncology Target Price
Pyxis Oncology Analyst Ratings
Pyxis Oncology's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Pyxis Oncology stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Pyxis Oncology's financials, market performance, and future outlook by experienced professionals. Pyxis Oncology's historical ratings below, therefore, can serve as a valuable tool for investors.Know Pyxis Oncology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pyxis Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pyxis Oncology backward and forwards among themselves. Pyxis Oncology's institutional investor refers to the entity that pools money to purchase Pyxis Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2025-06-30 | 396.1 K | Pier 88 Investment Partners Llc | 2025-06-30 | 367.2 K | Jane Street Group Llc | 2025-06-30 | 336.1 K | Decheng Capital Llc | 2025-06-30 | 326.8 K | Schulhoff & Co Inc | 2025-06-30 | 275 K | Goldman Sachs Group Inc | 2025-06-30 | 224.3 K | State Street Corp | 2025-06-30 | 186.1 K | Bank Of New York Mellon Corp | 2025-06-30 | 165 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 160.2 K | Pfizer Inc | 2025-06-30 | 7 M | Laurion Capital Management Lp | 2025-06-30 | 3.6 M |
Pyxis Oncology's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 139.54 M.Market Cap |
|
Pyxis Oncology's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.50) | (0.53) | |
| Return On Capital Employed | (0.64) | (0.67) | |
| Return On Assets | (0.49) | (0.52) | |
| Return On Equity | (0.64) | (0.61) |
Determining Pyxis Oncology's profitability involves analyzing its financial statements and using various financial metrics to determine if Pyxis Oncology is a good buy. For example, gross profit margin measures Pyxis Oncology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pyxis Oncology's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Pyxis Oncology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pyxis Oncology. Check Pyxis Oncology's Beneish M Score to see the likelihood of Pyxis Oncology's management manipulating its earnings.
Evaluate Pyxis Oncology's management efficiency
Pyxis Oncology has return on total asset (ROA) of (0.3125) % which means that it has lost $0.3125 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.748) %, meaning that it created substantial loss on money invested by shareholders. Pyxis Oncology's management efficiency ratios could be used to measure how well Pyxis Oncology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.53 in 2025. Return On Capital Employed is likely to drop to -0.67 in 2025. At this time, Pyxis Oncology's Non Currrent Assets Other are comparatively stable compared to the past year. Total Current Assets is likely to gain to about 137.5 M in 2025, whereas Net Tangible Assets are likely to drop slightly above 111 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.07 | 2.35 | |
| Tangible Book Value Per Share | 2.02 | 2.26 | |
| Enterprise Value Over EBITDA | (1.40) | (1.47) | |
| Price Book Value Ratio | 0.76 | 0.79 | |
| Enterprise Value Multiple | (1.40) | (1.47) | |
| Price Fair Value | 0.76 | 0.79 | |
| Enterprise Value | 91.9 M | 87.3 M |
The management strategies employed by Pyxis Oncology's are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Beta 1.334 |
Basic technical analysis of Pyxis Stock
As of the 4th of October, Pyxis Oncology holds the Risk Adjusted Performance of 0.1522, semi deviation of 2.95, and Coefficient Of Variation of 415.45. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pyxis Oncology, as well as the relationship between them. Please check Pyxis Oncology standard deviation, as well as the relationship between the value at risk and kurtosis to decide if Pyxis Oncology is priced some-what accurately, providing market reflects its current price of 2.5 per share. Please also confirm Pyxis Oncology total risk alpha, which is currently at 0.7208 to check out the company can sustain itself at a future point.Pyxis Oncology's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pyxis Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pyxis Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pyxis Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pyxis Oncology's Outstanding Corporate Bonds
Pyxis Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pyxis Oncology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pyxis bonds can be classified according to their maturity, which is the date when Pyxis Oncology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| QORVO INC 3375 Corp BondUS74736KAJ07 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| QORVO INC 4375 Corp BondUS74736KAH41 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| QTELQD 2625 08 APR 31 Corp BondUS74735KAA07 | View |
Understand Pyxis Oncology's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Pyxis Oncology's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1522 | |||
| Market Risk Adjusted Performance | (3.29) | |||
| Mean Deviation | 3.89 | |||
| Semi Deviation | 2.95 | |||
| Downside Deviation | 3.62 | |||
| Coefficient Of Variation | 415.45 | |||
| Standard Deviation | 5.17 | |||
| Variance | 26.73 | |||
| Information Ratio | 0.2273 | |||
| Jensen Alpha | 1.26 | |||
| Total Risk Alpha | 0.7208 | |||
| Sortino Ratio | 0.325 | |||
| Treynor Ratio | (3.30) | |||
| Maximum Drawdown | 25.27 | |||
| Value At Risk | (6.63) | |||
| Potential Upside | 11.11 | |||
| Downside Variance | 13.08 | |||
| Semi Variance | 8.7 | |||
| Expected Short fall | (5.21) | |||
| Skewness | 1.02 | |||
| Kurtosis | 1.5 |
| Risk Adjusted Performance | 0.1522 | |||
| Market Risk Adjusted Performance | (3.29) | |||
| Mean Deviation | 3.89 | |||
| Semi Deviation | 2.95 | |||
| Downside Deviation | 3.62 | |||
| Coefficient Of Variation | 415.45 | |||
| Standard Deviation | 5.17 | |||
| Variance | 26.73 | |||
| Information Ratio | 0.2273 | |||
| Jensen Alpha | 1.26 | |||
| Total Risk Alpha | 0.7208 | |||
| Sortino Ratio | 0.325 | |||
| Treynor Ratio | (3.30) | |||
| Maximum Drawdown | 25.27 | |||
| Value At Risk | (6.63) | |||
| Potential Upside | 11.11 | |||
| Downside Variance | 13.08 | |||
| Semi Variance | 8.7 | |||
| Expected Short fall | (5.21) | |||
| Skewness | 1.02 | |||
| Kurtosis | 1.5 |
Consider Pyxis Oncology's intraday indicators
Pyxis Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pyxis Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Pyxis Oncology time-series forecasting models is one of many Pyxis Oncology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pyxis Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Pyxis Stock media impact
There is far too much social signal, news, headlines, and media speculation about Pyxis Oncology that are available to investors today. This information is accessible both publicly - through Pyxis Oncology's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Pyxis-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Pyxis Oncology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pyxis Oncology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pyxis Oncology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pyxis Oncology alpha.
Pyxis Oncology Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Pyxis Oncology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Pyxis Oncology Historical Investor Sentiment
Investor biases related to Pyxis Oncology's public news can be used to forecast risks associated with an investment in Pyxis. The trend in average sentiment can be used to explain how an investor holding Pyxis can time the market purely based on public headlines and social activities around Pyxis Oncology. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Pyxis Oncology's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Pyxis Oncology and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Pyxis Oncology news discussions. The higher the estimate score, the more favorable the investor's outlook on Pyxis Oncology.
Pyxis Oncology Corporate Management
| Thuy PharmD | VP Pharmacology | Profile | |
| Donna Regalado | Head Resources | Profile | |
| Jan Pinkas | Chief Officer | Profile | |
| Pamela MBA | Chief Officer | Profile | |
| Marsha Crochiere | Head Research | Profile | |
| Sondra Smyrnios | Head Operations | Profile | |
| Charles Gombar | Senior Management | Profile |
Additional Tools for Pyxis Stock Analysis
When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.